Market Access

Duplicate rebates have resulted in revenue leakage for manufacturers.

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures.

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law PLLC, discusses recent moves by CVS and Express Scripts to follow Mark Cuban's drug plus model.

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

All healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives.

Analysis examines how social and healthcare factors play a role.

Soaring healthcare costs show little sign of abating in 2024, and concerns about the affordability of medications and medical services continue to grow, despite investments in technology, clinical innovation, and efforts to manage utilization and waste.

Morgan Company report makes the case for expanding coverage for GLP-1s beyond diabetes treatment and into the weight loss class, but are employers on board?

While often portrayed in a negative light, it is important to find a balanced perspective on its role in the pharma sector.

US biosimilars market projected to grow from less than $10 billion in 2022 to more than $100 billion by 2029.

Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.

Over the past year, Pharma Commerce’s digital coverage featured a variety of subject matters, ranging from how to calculate 340B prices, to the future of pharmacy.

The most popular pieces pertaining to the supply chain featured ADMs, vaccine supply chains, and wholesalers.

In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.

Will result from Medicare reforms, despite increased drug uptake.

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

Eli Lilly and Company's obesity drug Zepbound (tirzepatide) has a list price of $1,059.87, which is approximately 20% less than the 2.4 mg semaglutide injection indicated for weight loss.

Investigation notes a need for greater transparency in 340B program revenue and strengthened enforcement authority for the Health Resources and Services Administration.

ClearNetwork will be available for a plan sponsor’s list of covered generic, branded, and specialty drugs across 65,000 retail pharmacies in the Express Scripts network.

Blue Fin Group exec speaks on his upcoming feature.

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener.

Director of Berkeley Research Group explains changes to 340B moving forward.

Berkeley Research Group executive speaks about the role of manufacturers in 340B pricing.

Berkeley Research Group Director discusses what to expect at his upcoming session.

Tirzepatide (Zepbound; Eli Lilly and Company) will hit the US market by the end of 2023 with a list price of $1,059.87.

Study describes how biotech startups can avoid competing with large pharma companies for financing.

HDA research reveals that 95% of pharma transactions move through the traditional distribution channel.

Payers won’t let these products break the bank.

The conference will focus on the full breadth of commercialization strategies and operations.

Boehringer Ingelheim’s unbranded adalimumab-adbm biosimilar will be available at an 81% discount to adalimumab (Humira).